ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial

ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that its pivotal Phase III ADVOCATE clinical trial of avacopan for anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis) hit its primary endpoints.